Antigen News and Research

RSS

AI-based strategy helps discover high-affinity antibody drugs

Scientists at University of California San Diego School of Medicine have developed an artificial intelligence (AI)-based strategy for discovering high-affinity antibody drugs.

31 Jan 2023

A high-throughput drug discovery assay for the endoplasmic reticulum aminopeptidase 1

The January 2023 issue of SLAS Discovery contains a collection of four full-length articles and one technical brief covering cancer research, high-throughput screening (HTS) assay development and other drug discovery exploration.

31 Jan 2023

Novel adoptive T cell receptor therapy shows promising results for patients with solid tumors

Afamitresgene autoleucel (afami-cel; formerly ADP-A2M4), an adoptive T cell receptor (TCR) therapy targeting the MAGE-A4 cancer antigen, achieved clinically significant results for patients with multiple solid tumor types in a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

30 Jan 2023

New revelations on the immune system’s defenses against infections

Cells competing for a place in a germinal center confront a tough admissions process. Germinal centers, which form following exposure to a pathogen or vaccine, serve as a kind of immune system training academy, assisting B cells in refining their response to the threat.

18 Jan 2023

Novel blood biomarker predicts a favorable response to CART cell therapy

A MedUni Vienna research group identified a particularly potent biomarker for clinical response to CAR-T cell therapy, establishing the conditions for the most effective use of this innovative therapy for lymphoma treatment.

11 Jan 2023

Ultrafast, highly sensitive detection of proteins using simple laser irradiation

Protein detection based on antigen–antibody reaction is vital in early diagnosis of a wide range of diseases. How to effectively detect proteins, however, has frequently bedeviled researchers.

4 Jan 2023

Improving cancer immunotherapies with bioengineered synthetic gene circuits

In two distinct studies, scientists show how synthetic biology can be used to address a challenging problem in cancer immunotherapy: the way immunotherapy-related approaches focused on the short-term killing of tumor cells could fail to eradicate tumors because tumor growth occurs on longer timescales.

19 Dec 2022

The Native Antigen Company expands infectious disease portfolio to include Sudan Ebolavirus Boniface 1976 Glycoprotein

...

From The Native Antigen Company 8 Dec 2022

Insight into the treatment for Crimean Congo Hemorrhagic Fever Virus

The Crimean Congo Hemorrhagic Fever Virus can be prevented by therapeutically relevant human monoclonal antibodies, according to research led by the University of California, Riverside.

30 Nov 2022

The Native Antigen Company introduces new range of influenza antigens

The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the commercial launch of its latest range of influenza antigens for the southern hemisphere’s 2023 flu season.

From The Native Antigen Company 21 Nov 2022

Understanding immune cell function to improve vaccine efficacy

The immune system’s capacity to remember defeated disease-causing germs and avoid recurrent infections is still poorly understood, but a new study published in Science Immunology fills in some gaps.

From Rutgers University 8 Nov 2022

The Native Antigen Company expands its range of Omicron antigens to include BA.5 variant

The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the commercial launch of its latest SARS-CoV-2 antigens for the newly designated Omicron BA.5 variant.

From The Native Antigen Company 7 Nov 2022

Novel liposomal nanovaccines strongly activate cellular immunity

Cancer immunotherapies, such as immune checkpoint inhibition therapy, have been attracting attention in recent years as new methods for treating cancer.

2 Nov 2022

Innovative strategy for studying membrane proteins

Membrane proteins are vital therapeutic targets. They exist between the interior and exterior of human cells. Some of them, known as “transporters,” transport substances into and out of the cellular environment.

26 Oct 2022

Tiny DNA strand net in a low-cost test platform traps COVID-19 virus

According to a new study, tiny nets made of DNA strands can capture the spike protein of the virus that causes COVID-19, illuminating it for a quick yet accurate diagnostic test and preventing it from infecting cells, suggesting a new potential path to antiviral treatment.

26 Sep 2022

Study insights suggest novel targets for anti-cancer therapies

According to a recent study, cancers can avoid both the immune system and cancer treatments that depend on it, including CAR T cells that have been genetically altered.

12 Sep 2022

MD Anderson and Virogin Biotech collaborate to advance the development of investigational oncolytic viruses, treatments

The University of Texas MD Anderson Cancer Center and Virogin Biotech today announced a strategic collaboration to accelerate the development of investigational treatments, including oncolytic viruses and immunotherapies, for patients with advanced cancers.

12 Sep 2022

Microbiomes can help cure food allergies in mice

Many people with dietary allergies may have minor symptoms when they consume foods that trigger them, but for some, the consequences could be lethal. In lab experiments, a bacterial chemical called butyrate produced by healthy microbiomes has shown promise in preventing allergy reactions, but it is unpleasant to consume.

23 Aug 2022

Researchers create CAR T cells for cancer immunotherapy

In CAR T-cell immunotherapy, T cells taken from the patient’s own blood are modified to contain so-called chimeric antigen receptors (CAR), which provide the T cells the ability to target and eradicate tumor cells.

8 Aug 2022

Researchers find immune-effective ways to destroy cancer cells

Treatment with chimeric antigen receptor T cells (CAR T cells) is often the last hope for patients with lymphoma, multiple myeloma, or certain kinds of leukemia.

26 Jul 2022